by Joseph Mercola
In this interview, we continue the covid discussion with a medical expert from Argentina, Dr. Hector Carvallo, whose focus since early 2020 has been the prevention and treatment of covid.
Carvallo graduated from medical school in 1981 — the same year AIDS emerged as a global pandemic. In the first two years, AIDS killed 2 million people. Since 1981, it has claimed the lives of 35 million. While officially retired for a couple of years, the 2020 covid pandemic brought him out of retirement.
“My first fire baptism was with AIDS,” he says. “I have dedicated my professional time to teaching and assisting. I graduated as a professor in 1996, and worked as a professor for the School of Medicine in Buenos Aires, which is public. Later, I was an associate professor of internal medicine for two private schools of medicine until I retired a couple of years ago.”
Interestingly, Carvallo had experience with ivermectin as an antiviral before the covid outbreak. Argentinian doctors were using it against dengue fever, which is endemic in Argentina. So, when SARS-CoV-2 emerged, they decided to take another look at the drug to see if it might be useful.
“We came across some studies that were being conducted in Australia at the Monash University by people like Dr. Kylie Wagstaff,” Carvallo says. “We supposed that it would be very useful because the virology in effect already proved that, and we decided — even before they published their first findings — to replicate what they were doing, but in vivo. That is, not in the laboratory but in human beings.”
In early April 2020, Carvallo and his team developed two trials submitted to the National Library of Medicine in the United States. One was for preexposure (prevention) and the other for treatment. In both cases, ivermectin was used as an adjunct to other compounds, as they didn’t believe it was a silver bullet by itself.
For preventive purposes, they used ivermectin together with carrageenan, a food emulsifier and thickener that has a long history of use in both food and medicine. According to Carvallo, carrageenan has antiviral effects too, so the ivermectin was used in combination with topical carrageenan, administered through the nose and mucus membranes of the mouth.
In the treatment trial, ivermectin was combined with aspirin for mild cases, aspirin and corticosteroids for moderately severe cases, and enoxaparin (an anticoagulant drug) for severe cases.
These drug combinations were selected based on what was known about other viruses that cause similar health effects as SARS-CoV-2, such as the rhabdovirus’ effect on neurology, the paramyxovirus, which causes hyperinflammation in the lungs, and the dengue virus, which overamplifies the immune system.